

Senores Pharmaceuticals begins operations at greenfield API facility

Mehsana, India, 26th February 2025 – Senores Pharmaceuticals Limited (‘Senores’ or ‘SPL’) has today inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (‘API’) plant located at Survey No. 1503, Rajpur, Kadi, Mehsana – 382 715, Gujarat.

Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores’ second API manufacturing facility, adding significantly to the existing API manufacturing capabilities.

Commenting on the inauguration, **Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“We are delighted to commence operations at our greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the Regulated Markets, especially in the CDMO/CMO business.”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited (‘Senores’) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies’ current portfolio includes 24 ANDA and 21 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 260 product registrations and 530 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US, which is USFDA approved and DEA/BAA compliant, and the other is in Chhatral, Ahmedabad, India, approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

MEDIA RELEASE

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: U24290GJ2017PLC100263

Mr. Deval Shah

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899